Evkeeza
Active Ingredient(s): Evinacumab-dgnbFDA Approved: * February 11, 2021
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Cholesterol
Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).[1][2] Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.[2] Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).[... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.